{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-039211","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.409470+00:00","generated_at":"2026-06-08T01:08:39.507353+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nasdaq grants Avalo Therapeutics extension to Dec 29 to regain $1 bid price","bullets":["Received Nasdaq notice on Nov 14, 2023 of Panel granting exception from MVLS and bid price rules until Dec 29, 2023.","Condition 1 already met: Company filed Form 10-Q on Nov 9 showing stockholders' equity of $14.7M, satisfying Nasdaq equity requirement.","Condition 2: Must maintain closing bid price of $1.00 for ten consecutive sessions by Dec 29 to avoid delisting.","Previously, on Sep 13, Nasdaq notified Company of low-priced stock rule due to bid price <=$0.10 for ten consecutive days.","No assurance of regaining compliance; risk of delisting remains."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-039211","json":"https://secwatch.observer/filing/0001628280-23-039211.json","markdown":"https://secwatch.observer/filing/0001628280-23-039211.md","text":"https://secwatch.observer/filing/0001628280-23-039211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/0001628280-23-039211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/avtx-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:08:39.507353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"110e87337dafb07b70a12343ddf18d4a86e54d7e","claim":"Avalo Therapeutics, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2), 5550(b)(1)).","evidence_excerpt":"November 14, 2023, the Company received written notice from Nasdaq (the “November Notification Letter”) that the Panel had granted the Company an exception from compliance with the MVLS Rule and the Bid Price Rule and extension of continued listing until December 29, 2023, subject to the following: 1. On or before November 9, 2023, the Company will demonstrate compliance with Listing Rule 5550(b)(1) by filing its Form 10-Q with the SEC evidencing a minimum of $2.5million in stockholders’ equity; and 2. On or before December 29, 2023, the Company will demonstrate compliance with Listing Rule 55","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/0001628280-23-039211-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"hearing update"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5810(c)(3)(A)(iii), 5550(a)(2), 5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"846d735f8e8de0fbed48c3b189695736ad8bd10e","claim":"Avalo Therapeutics, Inc. received a nasdaq hearing update notice regarding market value (rules 5550(b)(2), 5810(c)(3)(A), 5810(c)(3)(C)).","evidence_excerpt":"November 14, 2023, the Company received written notice from Nasdaq (the “November Notification Letter”) that the Panel had granted the Company an exception from compliance with the MVLS Rule and the Bid Price Rule and extension of continued listing until December 29, 2023, subject to the following: 1. On or before November 9, 2023, the Company will demonstrate compliance with Listing Rule 5550(b)(1) by filing its Form 10-Q with the SEC evidencing a minimum of $2.5million in stockholders’ equity; and 2. On or before December 29, 2023, the Company will demonstrate compliance with Listing Rule 55","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/0001628280-23-039211-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"hearing update"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2), 5810(c)(3)(A), 5810(c)(3)(C)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}